Translation for information purpose

CONVENING NOTICE TO ATTEND THE ORDINARY AND EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS

Shareholders are invited to attend:

The Ordinary and Extraordinary General Meeting of Shareholders of Mithra Pharmaceuticals SA (the "Company") that will take place on Thursday 19th May 2022 at 2 pm, at Mithra CDMO, rue de l'Expansion 57, 4400 Flémalle (Belgium), in the presence of the Public Notary Jean-Michel Gauthy, acting Rue Hoyoux 87, 4040 Herstal, for the purpose of considering and voting on the following agenda:

A. Ordinary General Shareholders' Meeting:

1. Review of the annual report 2021 including the management report 2021;
2. Review of the consolidated annual accounts closed on the 31st of December 2021;
3. Review of the statutory auditor's report regarding the consolidated and non-consolidated annual accounts closed on the 31st of December 2021;
4. Review and approval of the non-consolidated annual accounts closed on the 31st of December 2021;

Proposed resolution: The General Meeting approves the non-consolidated annual accounts closed on the 31st of December 2021.

5. Allocation of the results relating to the financial year ended on 31st December 2021;

Proposed resolution: The General Meeting approves the allocation of the results reflected in the annual accounts for the financial year ended on 31st December 2021;

6. Review and approval of the remuneration report closed on 31st December 2021;

Proposed resolution: The General Meeting approves the remuneration report related to the financial year closed on 31st December 2021;

7. Proposal to grant discharge to the statutory auditor;

Proposed resolution: The General Meeting grants special discharge to the statutory auditor for the performance of his mandate during the financial year closed on 31st December 2021.

8. Proposal to grant discharge of liability to the board of Directors;

Proposed resolution: The General Meeting grants, by separate vote, discharge of liability to each of the directors for the performance of their respective mandate during the financial year closed on 31st December 2021.

9. Approval in accordance with article 7:151 of the Belgian Companies and Associations Code;

On 4 February 2022, the Company and Goldman Sachs International ("GSI") entered into an equity financing agreement (the "Financing Agreement") pursuant to which the Company may require GSI (subject to certain conditions) to provide financing to the Company in an aggregate amount of up to EUR 100,000,000.00 (including issue premium, as the case may be), through a number of drawings. In case a drawdown is accepted by GSI in accordance with the terms of the Finance Agreement, GSI is required to prepay the amount drawn to the Company. GSI has the option (subject to certain conditions) to convert the amount drawn (in whole or in part) into shares, by contribution in kind of the receivable underlying that amount, within a period of no more than 22 trading days following the second anniversary of the date of the Finance Agreement. The Financing Agreement provides (inter alia) that in the event of a merger or public takeover bid on the Company, the Modified Calculation Agent Adjustment would be applied as defined in sections 12.2(e) and 12.3(d) of the "2002 ISDA Equity Derivatives Definitions", as published by the International Swaps and Derivatives Association, Inc.

Proposed resolution: The general shareholders' meeting resolves to approve and ratify, in accordance with Article 7:151 of the Belgian Companies and Associations Code, all provisions of the Financing Agreement that come into effect upon the occurrence of a change of control, including, but not limited to, the application of the Modified Calculation Agent Adjustment as defined in sections 12.2(e) and 12.3(d) of the "2002 ISDA Equity Derivatives Definitions", as published by the International Swaps and Derivatives Association, Inc, and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders' meeting also grants a special power of attorney to each of the Company's directors, the Company's chief financial officer and the Company's corporate secretary, each of them acting individually, with the ability to sub-delegate and the power of subrogation, to complete the formalities required by article 7:151 of the Belgian Companies and Associations Code with regard to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the annexes to the Belgian Official Gazette.

B. Extraordinary General Shareholders' Meeting

1. Submission of reports;

1.1. Submission of the following reports in connection with the extension of the term of the LDA Warrants (as defined below): (a) the report of the board of directors of the Company prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code of 23 March 2019 (as amended) (the "Belgian Companies and Associations Code"), in complement to the report of the board of directors dated 18 June 2020, regarding the proposal to extend the term of the 690,000 subscription rights issued by the extraordinary general shareholders' meeting of the Company held on 22 July 2020 to the benefit of LDA Capital Limited (the "LDA Warrants") for a further two years; and (b) the report of the Company's statutory auditor prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code regarding the proposal to extend the term of the LDA Warrants for a further two years.
1.2. Submission of the following reports in connection with the extension of the term of the Share Lending Warrants (as defined below): (a) the report of the board of directors of the Company prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code, in complement to the report of the board of directors dated 18 June 2020, regarding the proposal to extend the respective term of the 300,000 subscription rights of the Company called the "Class A Share Lending Warrants", 300,000 subscription rights of the Company called the "Class B Share Lending Warrants ", and 300,000 subscription rights of the Company called "Class C Share Lending Warrants", issued by the extraordinary general shareholders' meeting of the Company held on 7 September 2020 to the benefit of, respectively, François Fornieri (in respect of the Class A Share Lending Warrants), Alychlo NV (in respect of the Class B Share Lending Warrants) and Noshaq SA (in respect of the Class C Share Lending Warrants) (collectively the "Share Lending Warrants"), for a further two years; and (b) the report of the Company's statutory auditor prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code regarding the proposal to extend the respective term of the Share Lending Warrants by a further two years.

2. Proposal to extend the term of the LDA Warrants;

Proposed resolution: The general shareholders' meeting resolves to approve the extension of the term of the LDA Warrants by two additional years from three years to five years from the date of issuance of the LDA Warrants (i.e., an extension from 22 July 2023 to 22 July 2025). No other amendments are made to the terms and conditions of the LDA Warrants. Accordingly, the general meeting confirms the resolutions passed at the extraordinary general shareholders' meeting of the Company held on 22 July 2020 in relation to the LDA Warrants but with an extended term as resolved here above, and approves the amended terms and conditions of the LDA Warrants, as set

out in the annex to the report of the board of directors referred to in agenda item 1.1(a), a copy of which will remain attached to the minutes reflecting this resolution.

3. Proposal to extend the term of the Class A Share Lending Warrants;

Proposed resolution: The general shareholders' meeting resolves to approve the extension of the term of the Class A Share Lending Warrants by two additional years from three years to five years from the date of issuance of the Class A Share Lending Warrants (i.e., an extension from 7 September 2023 to 7 September 2025). No other amendments are made to the terms and conditions of the Class A Share Lending Warrants. Accordingly, the general meeting confirms the resolutions passed at the extraordinary general shareholders' meeting of the Company held on 7 September 2020 in relation to the Class A Share Lending Warrants but with an extended term as resolved here above, and approves the amended terms and conditions of the Class A Share Lending Warrants, as set out in the annex to the report of the board of directors referred to in agenda item 1.2(a), a copy of which will remain attached to the minutes reflecting this resolution.

4. Proposal to extend the term of the Class B Share Lending Warrants;

Proposed resolution: The general shareholders' meeting resolves to approve the extension of the term of the Class B Share Lending Warrants by two additional years from three years to five years from the date of issuance of the Class B Share Lending Warrants (i.e., an extension from 7 September 2023 to 7 September 2025). No other amendments are made to the terms and conditions of the Class B Share Lending Warrants. Accordingly, the general meeting confirms the resolutions passed at the extraordinary general shareholders' meeting of the Company held on 7 September 2020 in relation to the Class B Share Lending Warrants but with an extended term as resolved here above, and approves the amended terms and conditions of the Class B Share Lending Warrants, as set out in the annex to the report of the board of directors referred to in agenda item 1.2(a), a copy of which will remain attached to the minutes reflecting this resolution.

5. Proposal to extend the term of the Class C Share Lending Warrants;

Proposed resolution: The general shareholders' meeting resolves to approve the extension of the term of the Class C Share Lending Warrants by two additional years from three years to five years from the date of issuance of the Class C Share Lending Warrants (i.e., an extension from 7 September 2023 to 7 September 2025). No other amendments are made to the terms and conditions of the Class C Share Lending Warrants. Accordingly, the general meeting confirms the resolutions passed at the extraordinary general shareholders' meeting of the Company held on 7 September 2020 in relation to the Class C Share Lending Warrants but with an extended term as resolved here above, and approves the amended terms and conditions of the Class C Share Lending Warrants, as set out in the annex to the report of the board of directors referred to in agenda item 1.2(a), a copy of which will remain attached to the minutes reflecting this resolution.

Attendance quorum, voting and majorities: According to the Belgian Companies and Associations Code, an attendance quorum of at least 50% of the outstanding shares must be present or represented at the extraordinary general shareholders' meeting for the deliberation and voting on the items on the agenda of the aforementioned extraordinary general shareholders' meeting. If such attendance quorum is not reached, a second extraordinary general shareholders' meeting will be convened for these agenda items, unless, as the case may be, decided otherwise on behalf of the board of directors, and the attendance quorum requirement will not apply to such second meeting.

Subject to applicable legal provisions, each share shall have one vote. In accordance with applicable law, the proposed resolutions referred to in the agenda of the extraordinary general shareholders' meeting shall be passed if they are approved by a majority of 75% of the votes validly cast by the shareholders. In accordance with article 7:135 of the Belgian Companies and Associations Code, the holders of subscription rights have the right to participate to the extraordinary general shareholders' meeting, but only with an advisory vote.

Notwithstanding the foregoing, as far as needed and applicable in accordance with article 7:193 of the Belgian Companies and Associations Code, each of respectively François Fornieri, Alychlo NV and Noshaq SA (each a "Beneficiary"), and each shareholders who act for the account of a Beneficiary, who are affiliated to a Beneficiary, who act for the account of the affiliates of a Beneficiary, or who act in concert with a Beneficiary will not participate in the vote in relation to, respectively, items 3, 4 and 5 of the agenda.

*****

Considering the COVID-19 pandemic, it is possible that our governments and public authorities may adapt the conditions and modalities for physical participation in the General Meeting. We reserve our rights to issue additional instructions in this regard. These measures are in the interest of the health of the individual security holders, as well as of the Company's employees and other persons responsible for organizing the General Meeting. Therefore, the Company recommends that shareholders of the Company who wish to participate in the General Meeting use, to the extent possible, the right to vote by mail or by proxy containing specific voting instructions for each proposed decision, granted to Ms. Fanny Rozenberg, Secretary of the Board of Directors of the Company, and not to attend the General Meeting in person. The Company will grant access to the General Meeting to security holders, proxy holders and any other persons only to the extent permitted by the measures taken or to be taken by the authorities, as applicable at the time of the General Meeting, and always taking into account the recommendations of the authorities, as well as safety and health considerations. In addition, holders of the Company's securities are encouraged to exercise their right to ask questions in writing concerning the items on the agenda of the General Meeting. Details of how to participate in the Ordinary Shareholders' Meeting are set out in this notice of meeting. The Company will also set up a videoconference to enable holders of the Company's securities who have duly registered for the General Meeting and who have duly completed and returned the notice of participation to the Company to follow the General Meeting remotely.

Videoconferencing will not be considered as an electronic means of communication to attend and vote at the General Meeting, as referred to in Article 7:137 of the Companies and Associations Code but will be an additional means for the security holders to follow the General Meeting. The Company will closely monitor the situation and applicable actions and may provide further updates relevant or impacting the Ordinary General Meeting on the Company's website (https://investors.mithra.com/fr/assemblee-des-actionnaires/).

In order to attend the Ordinary Shareholders' Meeting, shareholders must comply with the following formalities:

Only those people who are shareholders of Mithra Pharmaceuticals SA on 05 th May 2022 at midnight (Belgium time) (hereafter called the "record date") will have the right to participate and vote in the General Meeting on 19th May 2022, regardless of the number of shares held the day of the Meeting.

Holders of subscription rights and convertible bonds of the Company on 05th May 2022 at midnight (Belgium time), (hereinafter the "record date") will be entitled to participate but not to vote at the Meeting on 19 th May 2022.

Holders of registered shares who wish to attend the Meeting will not have to follow specific procedures to register their shares. The registration of their shares will result from Mithra Pharmaceuticals SA shareholders register on the record date. They will, however, have to confirm their desire to attend the Meeting by sending to the company the participation notice attached to the convening notice. Mithra Pharmaceuticals SA must have received such participation notices no later than 13 th May 2022. They may be sent either by regular mail to the address of the registered office of the Company or by fax or by e-mail (see useful information hereafter).

Holders of registered shares who wish to be represented at the Meeting will also have to send a duly filled out and signed proxy form (in writing or electronically, where the electronic signature must be a qualified electronic signature within the meaning of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23rd July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended), which is attached to the convening notice. Mithra Pharmaceuticals SA must have received such proxies no later than 13th May 2022. They may be sent either by regular mail to the address of the registered office of the Company or by fax or by e–mail (see useful information hereafter). Owners of registered shares wishing to be represented must also comply with the participation notification procedure described above.

Holders of dematerialized shares who wish to attend the Meeting must request a statement from the authorized account holder or from the settlement organization that holds their share account stating the number of dematerialized shares registered in their name in the books of these institutions on the record date and for which they have confirmed their desire to participate in the Meeting. Mithra Pharmaceuticals SA must have received such statements no later than 13th May 2022. They may be sent by regular mail to the address of the registered office of the Company, or by fax or by e-mail (see useful information hereafter).

Holders of dematerialized shares who wish to attend the Meeting also have to confirm their desire to attend the Meeting by sending to the Company the participation notice available on Mithra Pharmaceuticals SA's website (www.mithra.com). Mithra Pharmaceuticals SA must have received such participation notices no later than 13th May 2022. They may be sent either by regular mail to the address of the registered office of the Company or by fax or by e-mail (see useful information hereafter).

The holders of dematerialized shares who wish to be represented by proxy at the Meeting will additionally have to send a duly filled out and signed proxy form (in writing or electronically, where the electronic signature must be a qualified electronic signature within the meaning of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23rd July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended). Mithra Pharmaceuticals SA must have received such proxies no later than 13th May 2022. They may be sent either by regular mail to the address of the registered office of the Company or by fax or by e–mail (see useful information hereafter). The proxy from is available at the registered office of the Company and on its website (www.mithra.com).

An appointed proxy holder does not necessarily have to be a shareholder of Mithra Pharmaceuticals SA. While appointing a proxy holder, shareholders must in particular pay attention to potential conflicts of interest between them and the proxy holder (see article 7 :143, §4 of the Belgian Code on Companies and Associations). In view of the COVID-19 pandemic, the Company nevertheless recommends that security holders who wish to participate in the General Meeting use, to the extent possible, the right to vote by mail or by proxy containing specific voting instructions for each proposed decision granted to Ms. Fanny Rozenberg, Secretary of the Company's Board of Directors.

In accordance with article 7 :130 of the Belgium Code on Companies and Associations and under certain conditions, one (or several) shareholder(s) holding (together) at least 3% of the share capital may request the addition of new items to the agenda and/or submit new motions for a resolution relating to items on the agenda or to be added to the agenda. Any such request must be made in writing, duly signed (in writing or electronically, the electronic signature must be a qualified electronic signature within the meaning of Regulation (EU) No 910/2014 of the European Parliament and of the Council of 23rd July 2014 on electronic identification and trust services for electronic transactions in the internal market and repealing Directive 1999/93/EC, as amended). Mithra Pharmaceuticals SA must have received such requests no later than 27 th April 2022. These requests may be sent either by regular mail to the address of its registered office of the Company, or by fax or by e-mail (see useful information hereafter). The Company shall acknowledge receipt of these requests to this address specified by the shareholder, within 48 hours as from receipt of the requests.

Such request shall be dealt with only if it is accompanied by a document attesting possession of the aforementioned share percentage (in the case of registered shares, a certificate certifying the registration of the corresponding shares in the share register of the Company; for dematerialized shares, a certificate issued by an authorized account holder or settlement organization, certifying the registration of the shares in one or more accounts).

Should certain shareholders exercise this right, the Company shall, no later than on 04 th May 2022, publish, as the original agenda was, an updated agenda with additional items and proposed resolutions related thereto and/or additional proposed resolutions. Simultaneously, the Company will make amended forms for voting by proxy available to its shareholders through its website (www.mithra.com). However, proxies notified to the Company prior to the publication of an updated agenda remain valid for the items referred to in such proxies.

As an exception, for the items for which new proposed resolutions are submitted in accordance with article 7:130 of the Belgium Code on Companies and Associations, the proxy holder may, at the Meeting, deviate from instructions given by the principal if performing such instructions would compromise the principal's interests. He must inform the principal. The proxy must mention whether the proxy holder may vote on new topics added to the agenda or whether he must abstain from voting.

The items or motions for a resolution submitted will be dealt with only if the concerned shareholder(s) have completed the notification and registration process.

1. Shareholders who have complied with the formalities to attend the Meeting may also, prior to the Meeting, submit in writing to the Board of Directors questions regarding items on the agenda or its reports, as well as to the External Auditor with regard to his report. These questions must reach Mithra Pharmaceuticals SA no later than 13 th May 2022 and may be sent either by regular mail to its registered office or by fax or by e-mail (see useful information hereafter).
1. Each holder of registered shares or, upon presentation of a statement by an authorized account holder or a settlement organization certifying the number of dematerialized shares registered in the name of the shareholder, each holder of dematerialized share may consult and obtain a free copy of all the documents, including the proxy form and, for each item on the agenda not submitted to a vote, the comment of the board of directors, related to the Meeting of 19th May 2022 which, by law, must be available to shareholders, at the registered office of the Company, on business days and within normal business hours, as from 19th April 2022. Requests to obtain free copies may be sent either by regular mail to the address of its registered office of the Company, or by fax or by e-mail (see useful information hereafter). All these documents are also available on the website of Mithra Pharmaceuticals SA as from 19th April 2022.
1. It is recalled that one share is equal to one vote.
1. Please note that the signatures on the attendance list will be accepted as from 1:00 pm on 19 th May 2022. In order to attend the Meeting, shareholders or proxy holders must attest their identity, and representatives of legal entities must provide documents attesting of their identity and representation powers, at the latest immediately before the start of the meeting. Otherwise, participation to the meeting may be refused.

For the Board of Directors,

Useful information : Mithra Pharmaceuticals SA Assemblée Générale 5, rue Saint-Georges 4000 Liège

Fax: +32(0)4.349.28.21 E-mail : [email protected] Site Internet : http://www.mithra.com

Translation for information purpose

AGENDA OF THE ORDINARY AND EXTRAORDINARY GENERAL MEETING OF SECURITY HOLDERS DATED 19TH MAY 2022

A) Ordinary General Shareholders' Meeting
1. Review of the annual report 2021 including the management report 2021;
2. Review of the consolidated annual accounts closed on the 31st of December 2021;
3. Review of the statutory auditor's report regarding the consolidated and non-consolidated annual accounts closed on the 31st of December 2021;
4. Review and approval of the non-consolidated annual accounts closed on the 31st of December 2021;

Proposed resolution: The General Meeting approves the non-consolidated annual accounts closed on the 31 st of December 2021.

Allocation of the results relating to the financial year ended 31st December 2021;

Proposed resolution: The General Meeting approves the allocation of the results reflected in the annual accounts for the financial year ended on 31st December 2021.

6. Review and approval of the remuneration report closed on 31st December 2021;

Proposed resolution: The General Meeting approves the remuneration report related to the financial year closed on 31st December 2021.

7. Proposal to grant discharge to the statutory auditor;

Proposed resolution: The General Meeting grants special discharge to the statutory auditor for the performance of his mandate during the financial year closed on 31st December 2021.

8. Proposal to grant discharge of liability to the board of Directors;

Proposed resolution: The General Meeting grants, by separate vote, discharge of liability to each of the Directors for the performance of their respective mandate during the financial year closed on 31st December 2021.

9. Approval in accordance with article 7:151 of the Belgian Companies and Associations Code;

B) Extraordinary General Shareholders' Meeting

1. Submission of reports;
- 1.1. Submission of the following reports in connection with the extension of the term of the LDA Warrants (as defined below): (a) the report of the board of directors of the Company prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code of 23 March 2019 (as amended) (the "Belgian Companies and Associations Code"), in complement to the report of the board of directors dated 18 June 2020, regarding the proposal to extend the term of the 690,000 subscription rights issued by the extraordinary general shareholders' meeting of the Company held on 22 July 2020 to the benefit of LDA Capital Limited (the "LDA Warrants") for a further two years; and (b) the report of the Company's statutory auditor prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code regarding the proposal to extend the term of the LDA Warrants for a further two years.
- 1.2. Submission of the following reports in connection with the extension of the term of the Share Lending Warrants (as defined below): (a) the report of the board of directors of the Company prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code, in complement to the report of the board of directors dated 18 June 2020, regarding the proposal to extend the respective term of the 300,000 subscription rights of the Company called the "Class A Share Lending Warrants", 300,000 subscription rights of the Company called the "Class B Share Lending Warrants ", and 300,000 subscription rights of the Company called "Class C Share Lending Warrants", issued by the extraordinary general shareholders' meeting of the Company held on 7 September 2020 to the benefit of, respectively, François Fornieri (in respect of the Class A Share Lending Warrants), Alychlo NV (in respect of the Class B Share Lending Warrants) and Noshaq SA (in respect of the Class C Share Lending Warrants) (collectively the "Share Lending Warrants"), for a further two years; and (b) the report of the Company's statutory auditor prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code regarding the proposal to extend the respective term of the Share Lending Warrants by a further two years.

2. Proposal to extend the term of the LDA Warrants;

out in the annex to the report of the board of directors referred to in agenda item 1.1(a), a copy of which will remain attached to the minutes reflecting this resolution.

3. Proposal to extend the term of the Class A Share Lending Warrants;

4. Proposal to extend the term of the Class B Share Lending Warrants;

5. Proposal to extend the term of the Class C Share Lending Warrants;

*****

Translation for information purpose

EXPLANATORY NOTE: ORDINARY AND EXTRAORDINARY GENERAL SHAREHOLDERS' MEETING 19TH May 2022

This note was drawn up in application of article 7:129, §2 of the Belgian Code on Companies and Associations ("CCA") and contains explanations on some of the items listed on the agenda of the Ordinary and Extraordinary General Shareholders' Meeting.

For more information on the Ordinary and Extraordinary General Shareholders' Meeting and the applicable formalities, we refer you to the text of the convening notice which can be found on Mithra Pharmaceutical's website (www.mithra.com ).

Item 1: Review of the annual report 2021 including the management report 2021

Comment: The Board of Directors has first drawn up an annual report, including the consolidated management report on the financial year 2021's operations in which all legally prescribed mentions have been addressed (provision 3:32 CCA). The Board of Directors has, then, drafted the statutory management report as prescribed by provisions 3:5 and following of the CCA on the activities of Mithra Pharmaceuticals SA (the "Company") related to the financial year 2021.

This item is for information purposes only and does not require the adoption of a decision.

Item 2: Review of the consolidated accounts closed on the 31st of December 2021

Comment: In accordance with Articles 3:31 and 3:35 of the CCA, the consolidated financial statements are prepared by the Board of Directors and communicated to the General Meeting. They are prepared applying the IAS / IFRS accounting standards adopted by the European Union.

This item is for information purposes only and does not require the adoption of a decision.

Item 3: Review of the statutory auditor's report related to the annual accounts closed on the 31st of December 2021

Comment: This report is prepared in accordance with Articles 3:74 and 3:75 of the CCA. The Statutory Auditor has submitted his report without reservation

This item is for information purposes only and does not require the adoption of a decision.

Item 4 and 5: Review and approval of the non-consolidated annual accounts closed on the 31st of December 2021 and allocation of results relating to the financial year ended 31st December 2021

Comment: In accordance with Articles 3:31 and 3:35 of the CCA, the consolidated financial statements are prepared by the Board of directors and communicated to the General Meeting. They are prepared applying the IAS / IFRS accounting standards adopted by the European Union.

The CCA requires that the General Shareholders' Meeting approves by a separate vote each year the annual accounts as well as the distribution of earnings and the setting of the dividend, if any.

It is proposed that the General Meeting approves the annual accounts for the financial year ended 31st December 2021, including the proposal to carry the losses forward.

Item 6: Review and approval of the remuneration report closed on the 31st December 2021

Comment: The CCA requires that the General Shareholders' Meeting approves the remuneration report each year by a separate vote. This report describes, among other things and in accordance with article 3:6, §3 paragraph 2 of the CCA, the remuneration policy for the members of the Board of directors as well as the members of the Executive Management Team and provides information regarding their remuneration.

It is proposed to approve the remuneration report. The vote of the General Assembly on this item will be an advisory vote

Item 7: Proposal to grant a discharge of liability in favor of the statutory auditor;

Comment: The CCA requires that the General Shareholders' Meeting, after approval of the annual accounts, grants by special vote, discharge of liability in favor of the Statutory Auditor.

It is proposed that the General Meeting grants discharge of liability to the Statutory Auditor for the performance of his mandate during the financial year ended 31st December 2021.

Item 8: Proposal to grant discharge of liability in favor of the directors for the financial year closed on 31st December 2021

Comment: Pursuant the CCA, the General Shareholders' Meeting, after approval of the annual accounts, votes by a separate vote on the discharge of liability of the directors.

It is proposed that the General Meeting grants discharge of liability to all the Directors for the performance of their respective mandate during the financial year ended 31 st December 2021.

Item 9: Approval of a change of control provision in accordance with Article 7: 151 of the Companies and Associations Code;

Comment: In accordance with article 7: 151 of the BCCA, the General Meeting is solely competent to approve change of control clauses by means of which third parties are granted rights having a substantial influence on the assets of the Company or causing a substantial debt or undertaking for the Company, if the exercise of such rights depends on the launch of a public takeover bid on the shares of the Company or a change of control thereof.

****

TRANSLATION FOR INFORMATION PURPOSE ONLY MITHRA PHARMACEUTICALS SA RUE SAINT GEORGES 5 4000 LIEGE BELGIQUE RPM LIEGE (DIVISION LIEGE) 0466.526.646

NOTICE OF ATTENDANCE

In order to be admitted to the Ordinary and Extraordinary General Meetings on 19th May 2022, MITHRA PHARMACEUTICALS SA (the "Company") must be in possession of the present notice of attendance by 13 th May 2022 at the latest.

The undersigned: (complete)

With his/her/its registered address at: (complete)

advise MITHRA PHARMACEUTICALS of his/her/its intention to attend the Ordinary and Extraordinary General Meeting that will be held on Thursday 19th May 2022 at 2 pm, rue de l'Expansion 57, 4400 Flémalle (Belgium), with all the shares registered at his/her/its name in the shareholders' register of the Company at the record date (that is 05 th May 2022 at midnight) and all the shares mentioned in the statement of ownership (at the said record date) sent to the Company (if participation with a different number of shares, please mention it hereafter).

Signed at……………………………………………. , on the……………………………………………. .

Signature(s)

Translation for information purpose

PROXY

In order to be valid, this proxy duly completed, dated and signed must reach MITHRA PHARMACEUTI-CALS SA no later than the 13th of May 2022, as described in the convening notice. This proxy can be sent by regular mail to the address of the registered office of the Company, by fax or by e-mail (see useful information hereafter). Proxies arriving late or not complying with the required formalities may be rejected.

The undersigned:

First Name, Last name /name of the company: (please complete)

(for legal persons) represented by: (please complete)

Residing at/having its registered office at: (please complete)

Owner of (please complete) ………………………. shares of Mithra Pharmaceuticals SA, with registered office at rue Saint-Georges 5, 4000 Liège,

Hereby appoints as proxy holder:

First Name, Last name/name of the company:

In order to:

A. Represent him/her/it at Mithra Pharmaceuticals SA's Ordinary and Extraordinary General Meeting that will be held on 19th May 2022, 2 pm at Mithra CDMO, rue de l'Expansion 57, 4400 Flémalle (Belgium) and to vote in his/her/its name on all the items on the following agenda in the manner hereby described. In case of lack of instructions on how to vote, abstention for one or more of the decisions proposed below or if for any reason the instructions given are not clear, please consider that this is a specific instruction to vote in favor of the proposed resolutions.

AGENDA AND VOTES

A. Ordinary General Shareholders' Meeting:

1. Review of the annual report 2021 including the management report 2021;
2. Review of the consolidated annual accounts closed on the 31st of December 2021;
3. Review of the statutory auditor's report regarding the consolidated and non-consolidated annual accounts closed on the 31st of December 2021;
4. Review and approval of the non-consolidated annual accounts closed on the 31st of December 2021;

Proposed resolution: The General Meeting approves the non-consolidated annual accounts closed on the 31st December 2021.

FOR AGAINST ABSTAIN

5. Allocation of the results relating to the financial year ended 31st December 2021;

Proposed resolution: The General Meeting approves the allocation of the results reflected in the annual accounts for the financial year ended 31st December 2021.

FOR AGAINST ABSTAIN

6. Review and approval of the remuneration report closed on 31st December 2021;

Proposed resolution: The General Meeting approves the remuneration report related to the financial year closed on 31st December 2021.

FOR AGAINST ABSTAIN

7. Proposal to grant discharge to the statutory auditor;

Proposed resolution: The General Meeting grants special discharge of liability to the statutory auditor for the performance of his mandate during the financial year closed on 31st December 2021.

8. Proposal to grant discharge of liability to the board of Directors

Proposed resolution: The General Meeting grants, by separate vote, discharge to each of the Directors for the performance of their respective mandate during the financial year closed on 31st December 2021.

1.- TicaConsult SRL, represented by Mr. Erik van den Eynden, a company registered under the law of Belgium, located Kapelaan Smitslaan 20, in 2650 Edegem and registered in B.C.E. under number 0636 809 156;

FOR AGAINST ABSTAIN

2.- Yima SRL, represented by Mr. François Fornieri, a company registered under the law of Belgium, located rue de l'Arbre-Sainte-Barbe 194, in 4000 Rocourt and registered in B.C.E. under number 0871.523.818;

FOR AGAINST ABSTAIN

3.- Sunathim SRL, represented by Mr. Ajit Shetty, a company registered under the law of Belgium, located Wielewaalstraat 18, in 2350 Vosselaar and registered in B.C.E under number 0474.893.093;

FOR AGAINST ABSTAIN

4.- Noshaq SA, represented by Mr. Gaëtan Servais, a company registered under the law of Belgium, located rue Lambert Lombard 3, Hôtel Copis, in 4000 Liège and registered in B.C.E under number 0426.624.509;

FOR AGAINST ABSTAIN

5.—Eva Consulting SRL, represented by Mr. Jean-Michel Foidart, a company registered under the law of Belgium, located sur la Heid 3 in 4870 Trooz and registered in B.C.E. under number 0874.027.804;

FOR AGAINST ABSTAIN

6.- Alius Modi SRL, represented by Mrs. Valérie Gordenne, a company registered under the law of Belgium, located Bèfve 22, in 4890 Thimister-Clermont and registered in B.C.E. under the number 0809.631.185;

FOR AGAINST ABSTAIN

7.- Mrs. Amel Tounsi, domiciled in place Jean Gabin 1, in 1090 Jette;

8.- Mrs. An Cloet, domiciled in rue Haute 4, in 1457 Walhain;

FOR AGAINST ABSTAIN

9.- Mrs. Liesbeth Weynants, domiciled avenue Emile de Béco 68, in 1050 Ixelles;

FOR AGAINST ABSTAIN

10.- Mrs. Patricia van Dijck, domiciled boulevard Général Wahis 39, in 1030 Bruxelles;

FOR AGAINST ABSTAIN

9. Approval in accordance with article 7:151 of the Belgian Companies and Associations Code

On 4 February 2022, the Company and Goldman Sachs International ("GSI") entered into an equity financing agreement (the "Financing Agreement") pursuant to which the Company may require GSI (subject to certain conditions) to provide financing to the Company in an aggregate amount of up to EUR 100,000,000.00 (including issue premium, as the case may be), through a number of drawings. In the event that a drawdown is accepted by GSI in accordance with the terms of the Finance Agreement, GSI is required to prepay the amount drawn to the Company. GSI has the option (subject to certain conditions) to convert the amount drawn (in whole or in part) into shares, by contribution in kind of the receivable underlying that amount, within a period of no more than 22 trading days following the second anniversary of the date of the Finance Agreement. The Financing Agreement provides (inter alia) that in the event of a merger or public takeover bid on the Company, would be applied the Modified Calculation Agent Adjustment as defined in sections 12.2(e) and 12.3(d) of the "2002 ISDA Equity Derivatives Definitions", as published by the International Swaps and Derivatives Association, Inc.

Proposed resolution: The general shareholders' meeting resolves to approve and ratify, in accordance with Article 7:151 of the Belgian Companies and Associations Code, all provisions of the Financing Agreement that come into effect upon the occurrence of a change of control, including, but not limited to, the application of the Modified Calculation Agent Adjustment as defined in sections 12.2(e) and 12.3(d) of the "2002 ISDA Equity Derivatives Definitions", as published by the International Swaps and Derivatives Association, Inc, and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders' meeting also grants a special power of attorney to each of the Company's directors, the Company's chief financial officer, and the Company's corporate secretary, each such person acting individually and with possibility of sub-delegation and the power of subrogation, to complete the formalities required by article 7:151 of the Belgian Companies and Associations Code with regard to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the annexes to the Belgian Official Gazette.

B. Extraordinary General Shareholders' Meeting

1. Submission of reports

1.1. Submission of the following reports in connection with the extension of the term of the LDA Warrants (as defined below): (a) the report of the board of directors of the Company prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code of 23 March 2019 (as amended) (the "Belgian Companies and Associations Code"), in complement to the report of the board of directors dated 18 June 2020, regarding the proposal to extend the term of the 690,000 subscription rights issued by the extraordinary general shareholders' meeting of the Company held on 22 July 2020 to the benefit of LDA Capital Limited (the "LDA Warrants") for a further two years; and (b) the report of the Company's statutory auditor prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code regarding the proposal to extend the term of the LDA Warrants for a further two years.
1.2. Submission of the following reports in connection with the extension of the term of the Share Lending Warrants (as defined below): (a) the report of the board of directors of the Company prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code, in complement to the report of the board of directors dated 18 June 2020, regarding the proposal to extend the respective term of the 300,000 subscription rights of the Company called the "Class A Share Lending Warrants", 300,000 subscription rights of the Company called the "Class B Share Lending Warrants ", and 300,000 subscription rights of the Company called "Class C Share Lending Warrants", issued by the extraordinary general shareholders' meeting of the Company held on 7 September 2020 to the benefit of, respectively, François Fornieri (in respect of the Class A Share Lending Warrants), Alychlo NV (in respect of the Class B Share Lending Warrants) and Noshaq SA (in respect of the Class C Share Lending Warrants) (collectively the "Share Lending Warrants"), for a further two years; and (b) the report of the Company's statutory auditor prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code regarding the proposal to extend the respective term of the Share Lending Warrants by a further two years.

2. Proposal to extend the term of the LDA Warrants

FOR AGAINST ABSTAIN

3. Proposal to extend the term of the Class A Share Lending Warrants

FOR AGAINST ABSTAIN

4. Proposal to extend the term of the Class B Share Lending Warrants

FOR AGAINST ABSTAIN

5. Proposal to extend the term of the Class C Share Lending Warrants

***

Provided he/she/it has completed the formalities referred to in the convening notice to that effect, and unless otherwise instructed, the undersigned notes that he/she/it will be represented at the Ordinary and Extraordinary General Meeting for the total number of shares it owns in the shareholders register or for which it has notified the ownership on the record date at midnight (Belgian time), on 05 th May 2022.

If new items have to be added to the agenda, and/or in case of submission of new motions for a resolution relating to items already on the agenda or which have been added at shareholders' request in compliance with article 7:130 of the Belgian Companies and Associations Code, the proxy holder is authorized, in compliance with article 7:130, §4, al.2 of the Belgian Companies and Associations Code, to withdraw from any possible instructions given by the shareholder if the execution of these instructions would compromising the interest of the shareholder.

If, after the effective date of this proxy, new items are added to the agenda, or new motions for a resolution relating to items already on the agenda or which have been added at the request of shareholders in compliance with article 7:130 of the Companies and Associations Code, the proxy holder:

is authorized to vote (*);
must abstain from voting (*).

(*) strike out the option not chosen. If none is strike out, the proxy holder will have to abstain from voting on the new items added to the agenda.

B. take part in all discussions on the items listed on the agenda for this meeting, cast all votes, pass and sign all acts, items, minutes, attendance lists and other documents:

C. in general, do all necessary actions as to properly execute this proxy, granting ratification in advance.

D. The undersigned hereby undertakes to indemnify the proxy for any liability which it may incur in relation to any act carried out for the purpose of implementing this proxy, provided that the proxy has respected the scope of the powers granted hereby. Moreover, the undersigned undertakes not to seek the nullity of any resolution approved by the proxy and not to seek damages from the proxy, provided that the proxy has respected the scope of the powers granted hereby.

Signed in……………………………………………………….., on………………………………………………………………….

Signature(s) must be preceded by the hand-written words "Good for proxy"

Useful Information Mithra Pharmaceuticals SA Assemblée Générale 5 rue Saint-Georges 4000 Liège Fax : +32(0)4.349.28.21 E-mail : [email protected] Site internet : www.mithra.com

We would appreciate if you could provide us with a telephone number and an e-mail address where we can reach you if necessary, as to validate this proxy and/or to provide you with additional information relating to the General Meeting:

Tel: ………………………………………………………………………………………………………………

E-mail: …………………………………………………………………………………………………………¹

¹ Your personal data will be processed in accordance with our Company's Privacy Policy, available on our website

Translation for information purpose

VOTING BY MAIL

In order to be valid, this vote duly completed, dated and signed must reach MITHRA PHARMACEUTI-CALS SA no later than the 13th May 2022, as described in the convening notice. This vote can be sent by regular mail to the address of the registered office of the Company, by fax or by e-mail (see useful information hereafter). Votes arriving late or not complying with the required formalities may be rejected.

The undersigned:

First Name, Last name /name of the company: (please complete)

(for legal persons) represented by: (please complete)

Residing at/having its registered office at: (please complete)

Owner of (please complete) ……………………… shares of Mithra Pharmaceuticals SA, with registered office at rue Saint-Georges 5, 4000 Liège,

Hereby declare its willingness to vote as follows on the items on the agenda of the Ordinary and Extraordinary General Meeting of Mithra Pharmaceuticals SA to be held on 19th May 2022, 2 p.m.

AGENDA AND VOTES

A. Ordinary General Shareholders' Meeting:

1. Review of the annual report 2021 including the management report 2021;
2. Review of the consolidated annual accounts closed on the 31st of December 2021;
3. Review of the statutory auditor's report regarding the consolidated and non-consolidated annual accounts closed on the 31st of December 2021;

4. Review and approval of the non-consolidated annual accounts closed on the 31st of December 2021;

Proposed resolution: The General Meeting approves the non-consolidated annual accounts closed on the 31st December 2021.

FOR AGAINST ABSTAIN

5. Allocation of the results relating to the financial year ended 31st December 2021;

Proposed resolution: The General Meeting approves the allocation of the results reflected in the annual accounts for the financial year ended 31st December 2021.

FOR AGAINST ABSTAIN

6. Review and approval of the remuneration report closed on 31st December 2021;

Proposed resolution: The General Meeting approves the remuneration report related to the financial year closed on 31st December 2021.

FOR AGAINST ABSTAIN

7. Proposal to grant discharge to the statutory auditor;

Proposed resolution: The General Meeting grants special discharge of liability to the statutory auditor for the performance of his mandate during the financial year closed on 31st December 2021.

FOR AGAINST ABSTAIN

8. Proposal to grant discharge of liability to the board of Directors

FOR AGAINST ABSTAIN

3.- Sunathim SRL, represented by Mr. Ajit Shetty, a company registered under the law of Belgium, located Wielewaalstraat 18, in 2350 Vosselaar and registered in B.C.E under number 0474.893.093;

FOR AGAINST ABSTAIN

5.—Eva Consulting SRL, represented by Mr. Jean-Michel Foidart, a company registered under the law of Belgium, located sur la Heid 3 in 4870 Trooz and registered in B.C.E. under number 0874.027.804;

FOR AGAINST ABSTAIN

FOR AGAINST ABSTAIN
---------------------------

7.- Mrs. Amel Tounsi, domiciled in place Jean Gabin 1, in 1090 Jette;

FOR AGAINST ABSTAIN

8.- Mrs. An Cloet, domiciled in rue Haute 4, in 1457 Walhain;

FOR AGAINST ABSTAIN

9.- Mrs. Liesbeth Weynants, domiciled avenue Emile de Béco 68, in 1050 Ixelles;

FOR AGAINST ABSTAIN

10.- Mrs. Patricia van Dijck, domiciled boulevard Général Wahis 39, in 1030 Bruxelles;

9. Approval in accordance with article 7:151 of the Belgian Companies and Associations Code

On 4 February 2022, the Company and Goldman Sachs International ("GSI") entered into an equity financing agreement (the "Financing Agreement") pursuant to which the Company may require GSI (subject to certain conditions) to provide financing to the Company in an aggregate amount of up to EUR 100,000,000.00 (including issue premium, as the case may be), through a number of drawings. In the event that a drawdown is accepted by GSI in accordance with the terms of the Finance Agreement, GSI is required to prepay the amount drawn to the Company. GSI has the option (subject to certain conditions) to convert the amount drawn (in whole or in part) into shares, by contribution in kind of the receivable underlying that amount, within a period of no more than 22 trading days following the second anniversary of the date of the Finance Agreement. The Financing Agreement provides (inter alia) that in the event of a merger or public takeover bid on the Company, would be applied the Modified Calculation Agent Adjustment as defined in sections 12.2(e) and 12.3(d) of the "2002 ISDA Equity Derivatives Definitions", as published by the International Swaps and Derivatives Association, Inc.

Proposed resolution: The general shareholders' meeting resolves to approve and ratify, in accordance with Article 7:151 of the Belgian Companies and Associations Code, all provisions of the Financing Agreement that come into effect upon the occurrence of a change of control, including, but not limited to, the application of the Modified Calculation Agent Adjustment as defined in sections 12.2(e) and 12.3(d) of the "2002 ISDA Equity Derivatives Definitions", as published by the International Swaps and Derivatives Association, Inc, and which fall or could be considered to fall within the scope of article 7:151 of the Belgian Companies and Associations Code (relating to the granting of rights to third parties that substantially affect the Company's assets and liabilities, or give rise to a substantial debt or commitment on its behalf, when the exercise of these rights is subject to the launching of a public takeover bid on the shares of the Company or to a change in the control exercised over it). The general shareholders' meeting also grants a special power of attorney to each of the Company's directors, the Company's chief financial officer, and the Company's corporate secretary, each such person acting individually and with possibility of sub-delegation and the power of subrogation, to complete the formalities required by article 7:151 of the Belgian Companies and Associations Code with regard to this resolution, including, but not limited to, the execution of all documents and forms required for the publication of this resolution in the annexes to the Belgian Official Gazette.

B. Extraordinary General Shareholders' Meeting

1. Submission of reports

1.1. Submission of the following reports in connection with the extension of the term of the LDA Warrants (as defined below): (a) the report of the board of directors of the Company prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code of 23 March 2019 (as amended) (the "Belgian Companies and Associations Code"), in complement to the report of the board of directors dated 18 June 2020, regarding the proposal to extend the term of the 690,000 subscription rights issued by the extraordinary general shareholders' meeting of the Company held on 22 July 2020 to the benefit of LDA Capital Limited (the "LDA Warrants") for a further two years; and (b) the report of the Company's statutory auditor prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code regarding the proposal to extend the term of the LDA Warrants for a further two years.
1.2. Submission of the following reports in connection with the extension of the term of the Share Lending Warrants (as defined below): (a) the report of the board of directors of the Company prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code, in complement to the report of the board of directors dated 18 June 2020, regarding the proposal to extend the respective term of the 300,000 subscription rights of the Company called the "Class A Share Lending Warrants", 300,000 subscription rights of the Company called the "Class B Share Lending Warrants ", and 300,000 subscription rights of the Company called "Class C Share Lending Warrants", issued by the extraordinary general shareholders' meeting of the Company held on 7 September 2020 to the benefit of, respectively, François Fornieri (in respect of the Class A Share Lending Warrants), Alychlo NV (in respect of the Class B Share Lending Warrants) and Noshaq SA (in respect of the Class C Share Lending Warrants) (collectively the "Share Lending Warrants"), for a further two years; and (b) the report of the Company's statutory auditor prepared insofar as needed and applicable, in accordance with articles 7:180, 7:191 and 7:193 of the Belgian Companies and Associations Code regarding the proposal to extend the respective term of the Share Lending Warrants by a further two years.

2. Proposal to extend the term of the LDA Warrants

3. Proposal to extend the term of the Class A Share Lending Warrants

FOR AGAINST ABSTAIN

4. Proposal to extend the term of the Class B Share Lending Warrants

FOR AGAINST ABSTAIN

5. Proposal to extend the term of the Class C Share Lending Warrants

Provided he/she/it has completed the formalities referred to in the convening notice to that effect, and unless otherwise instructed, the undersigned notes that he/she/it will vote at the Ordinary General Meetings for the total number of shares it owns in the shareholders register or has notified the ownership on the record date at midnight (Belgian time), on 05 th May 2022.

***

If, after the effective date of this form, new items are added to the agenda, or new motions for a resolution relating to items on the agenda or to be added to the agenda are added at the request of shareholders in compliance with article 7:130 of the Companies Code, the shareholder:

votes in favour (*);
abstains from voting (*).

(*) strike out the option not chosen. If none is stricken out, the shareholder will have to abstain from voting on the new items added to the agendas.

Signed in……………………………………………………….., on………………………………………………………………….

Signature(s)

Useful Information Mithra Pharmaceuticals SA Assemblée Générale 5 rue Saint-Georges

4000 Liège Fax : +32(0)4.349.28.21 E-mail : [email protected] Site internet : www.mithra.com

We would appreciate if you could provide us with a telephone number and an e-mail address where we can reach you if necessary, to validate this vote and/or to provide you with additional information relating to the General Meeting:

Tel: ………………………………………………………………………………………………………………

E-mail: …………………………………………………………………………………………………………¹

¹ Your personal data will be processed in accordance with our Company's Privacy Policy, as published on our website

xxxx-xxxxxxxx	0466526646	2021	EUR	22.18.15	m02-f	xx/xx/xxxx	47		C-cap 1
---------------	------------	------	-----	----------	-------	------------	----	--	---------

COMPTES ANNUELS ET/OU AUTRES
DOCUMENTS À DÉPOSER EN VERTU DU
CODE DES SOCIÉTÉS ET DES ASSOCIATIONS

DONNÉES D'IDENTIFICATION (à la date du dépôt)

Dénomination : Mithra Pharmaceuticals
Forme juridique : Société anonyme
Adresse : Rue Saint-Georges	N° : 5	Boîte :
Code postal : 4000 Commune : Liège
Pays : Belgique
Registre des personnes morales (RPM) - Tribunal de l'entreprise de	Liège, division Liège
Adresse Internet :
Adresse e-mail :


	Numéro d'entreprise	0466.526.646


Date du dépôt du document le plus récent mentionnant la date de publication des actes constitutif et modificatif(s) des statuts		22-03-2022

Ce dépôt concerne :
les COMPTES ANNUELS en EURO	approuvés par l'assemblée générale du	19-05-2022
les AUTRES DOCUMENTS
relatifs à
l'exercice couvrant la période du	01-01-2021 au	31-12-2021
l'exercice précédent des comptes annuels du	01-01-2020 au	31-12-2020

Les montants relatifs à l'exercice précédent ne sont pas identiques à ceux publiés antérieurement.

Numéros des sections du document normalisé non déposées parce que sans objet :

C-cap 6.1, C-cap 6.2.1, C-cap 6.2.2, C-cap 6.2.4, C-cap 6.2.5, C-cap 6.3.4, C-cap 6.3.5, C-cap 6.4.2, C-cap 6.5.2, C-cap 6.18.1, C-cap 6.18.2, C-cap 6.20, C-cap 7, C-cap 8, C-cap 9, C-cap 11, C-cap 12, C-cap 13, C-cap 14

LISTE DES ADMINISTRATEURS, GÉRANTS ET COMMISSAIRES ET DÉCLARATION CONCERNANT UNE MISSION DE VÉRIFICATION OU DE REDRESSEMENT COMPLÉMENTAIRE

LISTE DES ADMINISTRATEURS, GÉRANTS ET COMMISSAIRES

LISTE COMPLÈTE des nom, prénoms, profession, domicile (adresse, numéro, code postal et commune) et fonction au sein de la société

TOUNSI AMEL Place Jean Gabin 1 1090 Jette
BELGIQUE Début de mandat : 2021-05-20	Fin de mandat : 2023-05-18	Administrateur
Cloet An Rue Haute 4 1457 Walhain
BELGIQUE Début de mandat : 2021-05-20	Fin de mandat : 2023-05-18	Administrateur
Weynants Liesbeth Avenue Emile de Beco 68 1050 Ixelles BELGIQUE
Début de mandat : 2021-05-20	Fin de mandat : 2023-05-18	Administrateur
Van Dijck Patricia Boulevard Général Wahis 3 1030 Schaerbeek BELGIQUE
Début de mandat : 2019-05-16	Fin de mandat : 2021-05-20	Administrateur
AHOK BV 0457927595 Steenvoordestraat 166 9070 Destelbergen BELGIQUE Début de mandat : 2019-05-16	Fin de mandat : 2021-05-20	Administrateur
Représenté directement ou indirectement par :
HOFFMAN Koen Steenvoordestraat 166 9070 Destelbergen BELGIQUE
ALIUS MODI srl 0809631185 Befve 22 4890 Thimister-Clermont
BELGIQUE Début de mandat : 2021-05-20	Fin de mandat : 2023-05-18	Administrateur
Représenté directement ou indirectement par :
Gordenne Valérie Befve 22 4890 Thimister-Clermont BELGIQUE

Eva Consulting SRL

0874027804 Sur la Heid 3 4870 Trooz BELGIQUE Début de mandat : 2021-05-20 Fin de mandat : 2023-05-18 Administrateur